Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HLX14 versus Prolia in postmenopausal women with osteoporosis at high risk of fracture
2022-002188-31Phase 3Terminated
- Sponsor
- Henlius
- Start
- Sep 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in osteoporosis comparing HLX14 with Prolia (2 arms). Primary endpoint: Percent change from baseline in bone mineral density at the lumbar spine. Started Sep 2022; status: terminated.
02
Drugs
denosumab-nxxpdenosumab
03
Conditions
osteoporosis
Beyond the preview
Go deeper on 2022-002188-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-002188-31.